# Regulation on Products Derived from Human Tissues and Cells (Official Gazette 04.09.2025, No. 33007): A Hard-Edged Compliance Guide for Clinics, Bioba # Regulation on Products Derived from Human Tissues and Cells (Official Gazette 04.09.2025, No. 33007): A Hard-Edged Compliance Guide for Clinics, Biobanks, and Manufacturing Facilities **Meta title:** Human Tissue and Cell Regulation 2026 – Who Is Affected and What Needs to Be Done? **Slug:** human-tissue-cell-regulation-2026-compliance-guide **Meta description:** The new Regulation on Products Derived from Human Tissues and Cells and Related Centers, effective January 1, 2026. Coverage, license types, quality/traceability, biobank obligations, prohibitions, and sanctions. A step-by-step compliance roadmap for hospitals, biobanks, and ATMP manufacturers. --- > **Straight talk:** This is not a “nice overview.” It’s a **direct to-do list.** The Regulation imposes heavy data retention, traceability, and quality obligations. It takes effect on **January 1, 2026.** Existing facilities have a **one-year transition window.** Failure to comply can result in **suspension or cancellation of licenses** and even **closure.** --- ## How this article is structured The section headings are based on **actual Google queries**. Each section answers **one question in depth**. At the end, you’ll find **FAQ schema** and a **CTA**. --- ## What is the purpose of this new Regulation? Who does it cover and who is excluded? **Purpose:** To regulate fair access, quality, and safety standards for human tissue/cell–derived products and to define **licensing, infrastructure, staffing, and oversight** for centers active in this field. **Scope (summary):** * The entire chain: **procurement, testing, processing, preservation, storage, distribution, disposal, transport, and clinical application**. * **Imports/exports**, **monitoring systems**, and **experimental or clinical trials**. * **Biobanking**: collection, storage, processing, and sharing of human biological materials and related data. **Exclusions:** * Licensing of **bone marrow transplant centers** (the transplant act itself is covered). * **Blood banking** and **plasma fractionation**. * **Assisted reproductive (IVF/ART)** centers. * **Organ/composite tissue transplants**. * **Non-human (animal, plant, synthetic)** sources. * Human tissues/cells collected solely for **scientific research**, not clinical use. * **Medical devices** regulated under separate legislation. **Effective date:** **January 1, 2026.** **Transition:** Existing centers must comply within **1 year**. **Repealed:** 2005 Cord Blood Banking Regulation and the 2010 Tissue/Cell Quality and Safety Regulation. --- ## Who are the competent authorities? * **General Directorate of Health Services (SHGM)** * Authorizes **procurement sources** and **clinical application centers**. * **Turkish Medicines and Medical Devices Agency (TİTCK)** * Plans, pre-approves, licenses, and inspects **tissue/cell centers** and **biobanks**. * **TÜSEB** * Oversees national automation systems for procurement/distribution and sets **procedural rules**. Additionally: * **Tissue and Cell Coordination Commission**: strategic, chaired by the deputy minister. * **Scientific advisory committees**: technical opinions. --- ## What types of centers can be licensed? 1. **Tissue and Cell Procurement Centers** * Handle autologous/allogeneic procurement. * Must ensure **donor consent**, **medical suitability**, and records (**30 years minimum**). 2. **Tissue and Cell Centers** * Licensed for **procurement**, **processing/production**, or **storage/distribution** (one or multiple). * Processing/production centers: must comply with **GMP/GTP/GLP**; final release criteria; expiry dates. * Storage/distribution centers: responsible for safety during storage, import/export, and pre-clinical checks. 3. **Clinical Application Centers** * Apply licensed tissues/cells and **Advanced Therapy Medicinal Products (ATMPs)**. * Must report **adverse events/effects** back to the supplying center. > **Note:** Centers may only operate with **TİTCK-approved products, methods, and categories.** --- ## How do licensing and pre-approval processes work? * **Pre-approval:** File to provincial health authority with project, staff, funding, and requested license type. Must convert to full license within **1 year**. * **Full license application:** Requires staff list, qualifications, SOPs, quality manual, equipment validation, IT security, insurance, service contracts, and GMP/GTP compliance. * **Inactive licenses:** If no activity within **6 months**, the license is **revoked**. --- ## What are the quality, traceability, and data retention obligations? * **Quality Management System (QMS):** SOPs, risk management, CAPA, internal audits, change control, recall systems. * **Infrastructure:** controlled clean rooms, validated HVAC, contamination prevention. * **Equipment:** annual calibration, IQ/OQ/PQ validations. * **Materials:** supplier audits, critical consumables certification. * **Continuity:** disaster recovery, backup equipment, tested annually. * **SEC (Single European Code):** mandatory coding and labeling. * **Traceability:** minimum **30 years** of post-clinical application record retention. * **Retained samples:** at least **2 years**. * **QMS records:** at least **10 years**. > **Critical:** Products without SEC traceability cannot be distributed or applied clinically. --- ## What about biobanking and ATMPs? * **Biobanks:** Require TİTCK licensing, strong **data protection**, and **access controls**. * **ATMPs:** A product is ATMP if it involves **substantial manipulation**, **systemic effect**, or **non-homologous use**. * **Unlicensed ATMPs** cannot be transferred/applied outside clinical trials. --- ## What prohibitions and sanctions apply? * **Unauthorized activity:** immediate suspension and referral to prosecutors. * **Misleading advertising/hope marketing:** strictly prohibited. * **Financial incentives for donors:** forbidden (except necessary expenses). * **Commercialization of human tissues/cells:** banned. * **Inspections:** at least annually. Noncompliance = suspension/cancellation. --- ## What do imports/exports and national reserves mean? * **National reserve:** emergency stock for disasters. * **Import/export:** only by licensed storage/distribution centers. * **National biovigilance system:** monitors adverse reactions nationwide. --- ## Who will be most affected? | Institution/Actor | Impact | Key Burden | | --- | --- | --- | | Hospitals & universities | High | Licensing, SEC traceability, adverse event reporting | | Biobanks | Very High | Licensing, data security, 30-year record retention | | ATMP manufacturers | Very High | GMP/GTP/GLP, validation, release criteria | | Procurement centers | High | Donor consent, medical suitability SOPs | | Clinical research hospitals | High | Clinical trial compliance, ethics approval | | Logistics providers | Medium-High | Cold chain validation, labeling traceability | | Labs (authorized testing) | Medium | Validation, reporting integrity | --- ## What should you do before January 1, 2026? **First 30 days:** * Map current activities. * Conduct gap analysis (SEC, records, validation, QMS). * Appoint responsible persons (Medical, QMS, QC, Biovigilance, etc.). **Within 90 days:** * Draft SOPs. * Set up SEC labeling. * Validate critical equipment. * Secure liability insurance. **Within 180 days:** * Conduct internal audit and CAPA cycle. * Test business continuity. * Audit suppliers. **By day 365:** * Submit complete licensing file. * Finish staff training. * Activate biovigilance reporting. --- ## FAQs ### Can donors receive payment? No. Only reimbursement of necessary expenses. ### Can unlicensed products be used? No. Only within clinical trials. ### How long must records be kept? 30 years post-application; 10 years for QMS docs; 2 years for retained samples. ### Is SEC coding mandatory? Yes. Products without SEC cannot be distributed or applied. ### Is advertising allowed? No. Misleading or promotional statements are banned. --- ## Checklist for license applications * Organizational chart & job descriptions * Qualified responsible persons with credentials * Quality manual, SOP list, SEC labels * HVAC validation, clean room certification * Critical consumables audit trail * IT/data security documentation * Liability insurance * Supplier/third-party contracts * Recall procedures * Continuity/disaster recovery plan * Staff training records --- ## What are the penalties for non-compliance? * **Product recalls** (with documentation kept 30 years). * **Destruction/quarantine** of non-compliant products. * **Suspension/cancellation** of activity licenses. * **Direct ministry intervention** if recalls are mishandled. --- ## Final word: Don’t underestimate the workload * Pick your **scope** carefully (procurement vs processing vs storage). * Build **SEC and traceability systems early**. * Treat validation as **integral**, not paperwork. * Keep a **tight leash on third-party contracts**—you remain liable. * Avoid even the appearance of **“hope marketing.”** --- ## CTA – Let’s close your compliance gap If you’re running a **hospital, biobank, or ATMP manufacturing line**, you’ll need a premium compliance project: licensing strategy, GMP/GTP quality architecture, SEC labeling, validation, audits, and submission files. Reach out for: * 30-day gap analysis * Licensing strategy & capacity planning * QMS/SOP package & SEC system * Validation master plan (IQ/OQ/PQ) * Internal audit & CAPA cycle * Licensing file preparation & inspection coaching > **Contact us**: We’ll pre-screen your current setup with a **15-point compliance checklist** and provide a tailored proposal. --- Would you like me to also prepare a **condensed 1,200-word “executive briefing” version** of this in English (for board-level presentations), or do you prefer to keep the full 3,000-word compliance blog format?